Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Rubi K. Li"'
Publikováno v:
Supportive Care in Cancer. 30:8655-8666
Autor:
Giorgi Dzagnidze, Justin Stebbing, Alexey Manikhas, Alexandru Eniu, Rubi K. Li, V. Baryash, Edvard Zhavrid, Joanna Pikiel, Vladimir Moiseyenko, Dmytro Boliukh, Yauheni Valerievich Baranau, Sang Joon Lee, Sunghyun Kim, Beatrice Tiangco
Publikováno v:
Breast Cancer Research and Treatment
Purpose Equivalent efficacy was demonstrated for the biosimilar CT-P6 and trastuzumab following neoadjuvant therapy for patients with human epidermal growth factor receptor-2 (HER2)-positive early breast cancer. Following adjuvant treatment, efficacy
Autor:
Alicia M. Vana, Patricia Banchero, Eduardo Yanez, Oleg Lipatov, A Thiele, Amy Freyman, Rubi K. Li, Fiona Hilton, Hryhoriy Adamchuk, Vladimir Ivanovich Vladimirov
Publikováno v:
Cancer Research. 80:P1-18
Background: Trazimera™ (PF-05280014) is a trastuzumab biosimilar. This multinational, randomized, double-blind, parallel-group study (NCT01989676) compared Trazimera with reference trastuzumab (Herceptin®) sourced from the EU (Herceptin-EU), each
Autor:
Rubi K. Li, Eriko Tokunaga, Hryhoriy Adamchuk, Vladimir Vladimirov, Eduardo Yanez, Keun Seok Lee, Igor Bondarenko, Alicia Vana, Fiona Hilton, Tomofumi Ishikawa, Kentaro Tajima, Oleg Lipatov
Publikováno v:
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 36(1)
PF-05280014 was compared with trastuzumab sourced from the European Union (trastuzumab-EU), each plus paclitaxel, as first-line treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer in a phase III study. Equivalence
Publikováno v:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerReferences. 30(11)
Hand-foot syndrome (HFS) and hand-foot skin reaction (HFSR) are common toxicities of several systemic cancer treatments. Multikinase inhibitor-induced HFSR is distinguished from chemotherapy-induced HFS in terms of pathogenesis, symptomatology, and t
Publikováno v:
Annals of Oncology. 33:S478
Autor:
Hirotaka Iwase, Petr V. Krivorotko, Marina Moreira Costa Zorzetto, Rubi K. Li, Rajesh Aggarwal, Reginald Ewesuedo, Sachin Hingmire, Ray Li, Mark D. Pegram, Keun Seok Lee, Amy Freyman, Elizabeth Tan-Chiu, Igor Bondarenko, Charles Zacharchuk, Joanna Pikiel, Alicia M. Vana, Donghua Yin
Publikováno v:
British Journal of Cancer
Background This randomised, double-blind study compared PF-05280014 (a trastuzumab biosimilar) with reference trastuzumab (Herceptin®) sourced from the European Union (trastuzumab-EU), when each was given with paclitaxel as first-line treatment for
Autor:
R. Verges, Peter Hohenberger, Aneta Borkowska, Eva Wardelmann, Herbert H. Loong, Judith V.M.G. Bovée, Lyn Austen, Vincent Servois, Zsusanna Papai, A. Mervoyer, Victor Moreno, Sylvie Bonvalot, Alexander J. Lazar, Lore Lapeire, Gabriel Kacso, Juliette Thariat, Piotr L. Rutkowski, Angel Montero, Thierry de Baere, Philippe Terrier, Marco Rastrelli, Antonio Casado Herraez, Angela Hong, Laurence Moureau-Zabotto, Alessandro Gronchi, S. Carrere, Rodica Anghel, Rubi K Li, Sorin Dema, Anne Ducassou, Marie-Pierre Sunyach, Guy Kantor, Ann Co, P. Agoston, Michaël Gebhart, Axel Le Cesne, Sylvie Helfre, Esma Saada-Bouzid, Cécile Le Péchoux, László Mangel, B. Tiangco, Teresa T. Sy-Ortin
Publikováno v:
The Lancet Oncology, 20(8), 1148-1159. ELSEVIER SCIENCE INC
Summary Background Pathological complete response to preoperative treatment in adults with soft-tissue sarcoma can be achieved in only a few patients receiving radiotherapy. This phase 2–3 trial evaluated the safety and efficacy of the hafnium oxid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1087e6215aa028883b746e07f548e550
http://hdl.handle.net/11577/3370880
http://hdl.handle.net/11577/3370880
Autor:
Andriy Rusyn, Vladimir Moiseyenko, Valeriy Baryash, Dmitry Komov, Dmytro Boliukh, Daniil Stroyakovskii, Sang Joon Lee, Edvard Zhavrid, Justin Stebbing, Joanna Pikiel, Giorgi Dzagnidze, Yauheni Valerievich Baranau, Sung Young Lee, Alexandru Eniu, Rubi K. Li, Gabriela Morar-Bolba, Alexey Manikhas, Francisco J. Esteva
Publikováno v:
The Lancet. Oncology. 18(7)
Summary Background CT-P6 is a proposed biosimilar to reference trastuzumab. In this study, we aimed to establish equivalence of CT-P6 to reference trastuzumab in neoadjuvant treatment of HER2-positive early-stage breast cancer. Methods In this random
Autor:
Rubi K. Li, Christina Ng, Paul N. Mainwaring, Philip W.K. Kwong, Se-Hoon Lee, Yung-Jue Bang, Hyun Cheol Chung, Susan Pitman Lowenthal, John Wen-Cheng Chang, Jinyu Yuan, Virote Sriuranpong, Chee Keong Toh
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 10:237-245
Aims We evaluated and compared the safety and efficacy of sunitinib in Asian and non-Asian patients with metastatic renal cell carcinoma enrolled in a previously reported global expanded access program. Methods Previously treated and treatment-naive